Widespread cefiderocol heteroresistance in carbapenem-resistant Gram-negative pathogens.
作者信息
Choby Jacob E, Ozturk Tugba, Satola Sarah W, Jacob Jesse T, Weiss David S
机构信息
Emory Antibiotic Resistance Center and Emory Vaccine Center, Atlanta, GA 30329, USA.
Emory Antibiotic Resistance Center and Emory Vaccine Center, Atlanta, GA 30329, USA; Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA; Georgia Emerging Infections Program, Georgia Department of Public Health, Atlanta, GA, USA.
出版信息
Lancet Infect Dis. 2021 May;21(5):597-598. doi: 10.1016/S1473-3099(21)00194-8.
Abstract
摘要
相似文献
1
Widespread cefiderocol heteroresistance in carbapenem-resistant Gram-negative pathogens.碳青霉烯耐药革兰氏阴性病原体中广泛存在的头孢地尔异质性耐药。
Lancet Infect Dis. 2021 May;21(5):597-598. doi: 10.1016/S1473-3099(21)00194-8.
2
Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.头孢地尔：一种具有抗碳青霉烯类和多药耐药革兰氏阴性杆菌活性的铁载体头孢菌素。
Drugs. 2019 Feb;79(3):271-289. doi: 10.1007/s40265-019-1055-2.
3
Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals.头孢地尔（S-649266）对从希腊医院住院患者中分离出的耐碳青霉烯革兰氏阴性菌的活性。
J Antimicrob Chemother. 2017 Jun 1;72(6):1704-1708. doi: 10.1093/jac/dkx049.
4
Activities of Cefiderocol with Simulated Human Plasma Concentrations against Carbapenem-Resistant Gram-Negative Bacilli in an Chemostat Model.在恒化器模型中，模拟人血浆浓度的头孢地尔对耐碳青霉烯革兰氏阴性杆菌的活性。
Antimicrob Agents Chemother. 2020 Oct 20;64(11). doi: 10.1128/AAC.01128-20.
5
Activity of the Siderophore Cephalosporin, Cefiderocol, against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem-Nonsusceptible Isolates (SIDERO-WT-2014 Study).头孢菌素类铁载体头孢地尔的活性对来自北美和欧洲的近期临床相关革兰氏阴性杆菌的收集，包括耐碳青霉烯类分离株（SIDERO-WT-2014 研究）。
Antimicrob Agents Chemother. 2017 Aug 24;61(9). doi: 10.1128/AAC.00093-17. Print 2017 Sep.
6
In Vitro Activity of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacilli Isolated from Patients in Canadian Intensive Care Units.在加拿大重症监护病房中分离的革兰氏阴性杆菌的体外活性研究：新型铁载体头孢菌素头孢地尔。
Diagn Microbiol Infect Dis. 2020 May;97(1):115012. doi: 10.1016/j.diagmicrobio.2020.115012. Epub 2020 Feb 4.
7
Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.头孢地尔优于亚胺培南西司他丁钠治疗革兰氏阴性尿路病原体引起的复杂性尿路感染：一项 2 期、随机、双盲、非劣效性试验。
Lancet Infect Dis. 2018 Dec;18(12):1319-1328. doi: 10.1016/S1473-3099(18)30554-1. Epub 2018 Oct 25.
8
Association between antibiotic consumption and the rate of carbapenem-resistant Gram-negative bacteria from China based on 153 tertiary hospitals data in 2014.基于 2014 年中国 153 家三级医院的数据，探讨抗生素使用与碳青霉烯类耐药革兰氏阴性菌发生率之间的关系。
Antimicrob Resist Infect Control. 2018 Nov 19;7:137. doi: 10.1186/s13756-018-0430-1. eCollection 2018.
9
Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship.头孢地尔罗（S-649266），一种新型的铁载体头孢菌素，对铜绿假单胞菌和其他革兰氏阴性病原体具有强大的活性，包括多药耐药菌：构效关系。
Eur J Med Chem. 2018 Jul 15;155:847-868. doi: 10.1016/j.ejmech.2018.06.014. Epub 2018 Jun 8.
10
Cefiderocol: A Siderophore Cephalosporin.头孢地尔：一种铁载体头孢菌素。
Ann Pharmacother. 2020 Dec;54(12):1215-1231. doi: 10.1177/1060028020929988. Epub 2020 Jun 10.
引用本文的文献
1
Combinatorial action of regulatory systems generates colistin heteroresistance.调节系统的组合作用产生了黏菌素异质性耐药。
bioRxiv. 2025 Aug 12:2025.08.11.668767. doi: 10.1101/2025.08.11.668767.
2
treatment strategies: a review of therapeutic challenges and considerations.治疗策略：治疗挑战与考量综述
Antimicrob Agents Chemother. 2025 Aug 6;69(8):e0106324. doi: 10.1128/aac.01063-24. Epub 2025 Jul 9.
3
Droplet microfluidics-based detection of rare antibiotic-resistant subpopulations in from bloodstream infections.基于微滴微流控技术检测血流感染中罕见的抗生素耐药亚群。
Sci Adv. 2025 Jul 4;11(27):eadv4558. doi: 10.1126/sciadv.adv4558.
4
Copy number flexibility facilitates heteroresistance to increasing antibiotic pressure and threatens the beta-lactam pipeline.拷贝数灵活性促进了对不断增加的抗生素压力的异质性耐药，并威胁到β-内酰胺类药物研发进程。
Nat Commun. 2025 Jul 1;16(1):5721. doi: 10.1038/s41467-025-60828-9.
5
Emergence of NDM-1- and OXA-23-Co-Producing ST1 Isolates from a Burn Unit in Spain.西班牙一家烧伤病房中同时产生NDM-1和OXA-23的ST1菌株的出现。
Microorganisms. 2025 May 16;13(5):1149. doi: 10.3390/microorganisms13051149.
6
Carbapenem-resistant Gram-negative bacteria exhibiting clinically undetected cefiderocol heteroresistance leads to treatment failure in a murine model of infection.表现出临床未检测到的头孢地尔异质性耐药的耐碳青霉烯革兰氏阴性菌导致感染小鼠模型治疗失败。
Front Microbiol. 2025 May 9;16:1496514. doi: 10.3389/fmicb.2025.1496514. eCollection 2025.
7
Overview of heteroresistance to multiple antibiotics in clinical isolates and combination therapeutic strategies.临床分离株中对多种抗生素的异质性耐药概述及联合治疗策略
JAC Antimicrob Resist. 2025 May 13;7(3):dlaf071. doi: 10.1093/jacamr/dlaf071. eCollection 2025 Jun.
8
The Multifaceted Landscape of Healthcare-Associated Infections Caused by Carbapenem-Resistant .耐碳青霉烯类药物引起的医疗保健相关感染的多方面情况
Microorganisms. 2025 Apr 5;13(4):829. doi: 10.3390/microorganisms13040829.
9
A Comprehensive Overview of Antibacterial Agents for Combating Multidrug-Resistant Bacteria: The Current Landscape, Development, Future Opportunities, and Challenges.对抗多重耐药菌的抗菌药物综合概述：现状、发展、未来机遇与挑战
Antibiotics (Basel). 2025 Feb 21;14(3):221. doi: 10.3390/antibiotics14030221.
10
Prevalence, misclassification, and clinical consequences of the heteroresistant phenotype in Escherichia coli bloodstream infections in patients in Uppsala, Sweden: a retrospective cohort study.瑞典乌普萨拉患者大肠埃希菌血流感染中异质性耐药表型的患病率、错误分类及临床后果：一项回顾性队列研究
Lancet Microbe. 2025 Apr;6(4):101010. doi: 10.1016/j.lanmic.2024.101010. Epub 2025 Jan 16.
本文引用的文献
1
Colistin Heteroresistance Is Largely Undetected among Carbapenem-Resistant in the United States.美碳青霉烯类耐药肠杆菌科中，黏菌素异质性耐药的检出率较低。
mBio. 2021 Jan 26;12(1):e02881-20. doi: 10.1128/mBio.02881-20.
2
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.头孢地尔罗或最佳现有治疗方案治疗碳青霉烯类耐药革兰氏阴性菌引起的严重感染的疗效和安全性（CREDIBLE-CR）：一项随机、开放标签、多中心、以病原体为重点、描述性的 3 期临床试验。
Lancet Infect Dis. 2021 Feb;21(2):226-240. doi: 10.1016/S1473-3099(20)30796-9. Epub 2020 Oct 12.
3
Carbapenem-Resistant Exhibiting Clinically Undetected Colistin Heteroresistance Leads to Treatment Failure in a Murine Model of Infection.碳青霉烯类耐药但临床检测不出的多粘菌素异质性耐药导致感染的小鼠模型治疗失败。
mBio. 2018 Mar 6;9(2):e02448-17. doi: 10.1128/mBio.02448-17.
4
Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016.2014 年至 2016 年全球范围内收集的碳青霉烯类药物不敏感和多重耐药革兰氏阴性杆菌的头孢菌素类抗生素头孢地尔的活性。
Antimicrob Agents Chemother. 2018 Jan 25;62(2). doi: 10.1128/AAC.01968-17. Print 2018 Feb.
5
Antibiotic failure mediated by a resistant subpopulation in Enterobacter cloacae.阴沟肠杆菌中耐药亚群介导的抗生素治疗失败。
Nat Microbiol. 2016 May 9;1(6):16053. doi: 10.1038/nmicrobiol.2016.53.
Zotero 插件